7 recruiting, 3 active not recruiting, 1 completed, 1 not yet recruiting. 4 Early Phase 1, 3 Not applicable, 3 Phase 2, 2 Phase 1, 1 Phase 4.
Follow 18F-rhPSMA-7.3: new trials by email Literature Review of 18F-rhPSMA-7.3 trials Research Report on 18F-rhPSMA-7.3
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| Prostate Specific Membrane Antigen (PSMA) Imaging for Detection of Residual and Metastatic Prostate Cancer Bicalutamide, Prostate-specific membrane antigen Positron Emission Tomography-Computed Tomography, 18F-rhPSMA-7.3 - Prostate Cancer, Recurrent Prostate Cancer | Phase 2 | Not yet recruiting | Washington University School of Medicine | 20 | 2026-10-31 | 2026-09-11 |
| Comparing a New PSMA Imaging Agent to MRI for Detecting Prostate Cancer, BEACON Trial Biopsy of Prostate, Biospecimen Collection, Computed Tomography - Prostate Carcinoma | Early Phase 1 | Recruiting | Jonsson Comprehensive Cancer Center | 30 | 2025-11-14 | 2026-03-10 |
| Utility of 18F-rhPSMA-7.3 in the Diagnosis of Prostate Cancer After Focal Gland Treatment 18F-rhPSMA-7.3 - Prostate Cancer | Not applicable | Recruiting | Hackensack Meridian Health | 70 | 2025-10-01 | 2026-03-23 |
| Androgen Deprivation Therapy (Relugolix) for the Improvement of Diagnostic Imaging (PSMA PET/CT Scan) in Patients With High Risk or Very High Risk Prostate Cancer, The EnrichPSMA Trial Biospecimen Collection, Computed Tomography, Flotufolastat F-18 Gallium - Prostate Adenocarcinoma, Stage IIC Prostate Cancer AJCC v8 | Phase 2 | Recruiting | Mayo Clinic | 30 | 2025-08-25 | 2026-09-23 |
| 18F-rhPSMA-7.3 PET/MRI in Prostate Cancer Active Surveillance: a Pilot Study 18F-rhPSMA-7.3 - Prostate Cancer | Early Phase 1 | Withdrawn | University of Alabama at Birmingham | 2025-04-30 | 2024-09-25 | |
| An Investigational Scan (18F-rhPSMA-7.3 PET-mpMRI) for Targeted Prostate Biopsy Using TRUS-MR Fusion Technique Flotufolastat F-18 Gallium, Magnetic Resonance Imaging, Multiparametric Magnetic Resonance Imaging - Prostate Carcinoma | Phase 2 | Recruiting | Emory University | 90 | 2025-04-18 | 2026-07-14 |
| An Investigational Scan (rhPSMA-7.3 PET/CT) for Detecting Biochemically Recurrent Prostate Cancer, ENLIGHTEN Trial Computed Tomography, Electronic Health Record Review, Flotufolastat F-18 Gallium - Biochemically Recurrent Prostate Carcinoma, Prostate Adenocarcinoma | Early Phase 1 | Recruiting | Northwestern University | 27 | 2025-04-11 | 2026-07-02 |
| [18F]-rhPSMA PET-CT Imaging Performance in Patients With Prostate Cancer Computed Tomography, Flotufolastat F-18 Gallium, Medical Device Usage and Evaluation - Prostate Carcinoma | Not applicable | Active not recruiting | City of Hope Medical Center | 20 | 2025-03-25 | 2026-04-27 |
| PSMAtrack-tracking Changes in PSMA-PET During Initial Therapy for Metastatic Hormone-sensitive Prostate Cancer 18F-rhPSMA-7.3, PET/CT - Metastatic Prostate Cancer, Hormone Sensitive Prostate Cancer | Phase 4 | Active not recruiting | Brigham and Women's Hospital | 20 | 2024-06-30 | 2025-11-05 |
| Accuracy of 18F-rhPSMA-7.3 PET/ MRI for Prediction of Lymph Node Metastasis in Localized High-Risk Prostate Cancer Bilateral Pelvic Lymph Node Dissection, Biospecimen Collection, Bone Scan - Localized Prostate Carcinoma, Oligometastatic Prostate Carcinoma | Not applicable | Recruiting | Mayo Clinic | 50 | 2024-06-11 | 2026-04-06 |
| Radioligand Therapy After PSMA PET Guided External Beam Radiotherapy for Treating Post-Prostatectomy Patients With Biochemically Recurrent Prostate Cancer Biospecimen Collection, Computed Tomography, External Beam Radiation Therapy - Biochemically Recurrent Prostate Carcinoma, Prostate Adenocarcinoma | Phase 1 | Active not recruiting | Emory University | 6 | 2023-11-29 | 2025-12-09 |
| rhPSMA-73 PET-MRI Imaging for the Detection of Prostate Cancer Among Men Who Are Otherwise Candidates for Active Surveillance Biopsy of Prostate, Decipher Prostate Cancer Test, Flotufolastat F-18 Gallium - Prostate Adenocarcinoma, Stage I Prostate Cancer AJCC v8 | Early Phase 1 | Recruiting | Northwestern University | 40 | 2023-06-07 | 2026-07-02 |
| An Investigational Scan (rh PSMA 7.3 PET/MRI) for the Detection of Recurrent Disease and Aid in Radiotherapy Planning in Biochemically Recurrent Prostate Cancer Fluorine F 18 rhPSMA-7.3, Magnetic Resonance Imaging, Positron Emission Tomography - Biochemically Recurrent Prostate Carcinoma, Localized Prostate Carcinoma | Phase 1 | Completed | M.D. Anderson Cancer Center | 29 | 2021-08-04 | 2024-10-23 |
Prostatic Neoplasms (10)
Emory University (2) · Mayo Clinic (2) · Northwestern University (2) · Brigham and Women's Hospital (1) · City of Hope Medical Center (1) · Hackensack Meridian Health (1) · Jonsson Comprehensive Cancer Center (1) · M.D. Anderson Cancer Center (1) · University of Alabama at Birmingham (1) · Washington University School of Medicine (1)
United States (12)
Ashley E Ross (2) · David M Schuster, MD, FACR (2) · Devaki Shilpa S Surasi (1) · Heather Jacene, MD (1) · Jack R. Andrews, MD (1) · Jeffrey Y Wong, MD (1) · Nitin Yerrman, MD (1) · Ram A. Pathak, MD (1) · Vikas Prasad, MD, PhD (1) · Wayne Brisbane (1)
PMID 38407630, PMID 40177325, PMID 41833067
P30CA060553 (2), P30CA138292 (2), P30CA033572 (1), U01CA113913 (1)